Financials Oxurion NV

Equities

OXUR

BE0003846632

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 09:54:35 2024-04-26 am EDT 5-day change 1st Jan Change
0.0001 EUR 0.00% Intraday chart for Oxurion NV 0.00% -88.89%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 138.5 113 97.84 70.95 7.81 2.923
Enterprise Value (EV) 1 53.42 62.26 74.13 73.06 12.24 13.58
P/E ratio -3.58 x -2.18 x -3.49 x -2.39 x -0.05 x -0.08 x
Yield - - - - - -
Capitalization / Revenue 26 x 28.6 x 47.1 x 62.9 x 13.1 x 11.1 x
EV / Revenue 10 x 15.8 x 35.7 x 64.8 x 20.6 x 51.6 x
EV / EBITDA -1.45 x -1.77 x -2.62 x -2.68 x -0.56 x -1.14 x
EV / FCF -3.46 x -3.48 x -4.58 x -4.37 x -0.99 x -2.03 x
FCF Yield -28.9% -28.7% -21.9% -22.9% -101% -49.2%
Price to Book 1.32 x 2.12 x 3.89 x -65.8 x -1.7 x -0.24 x
Nbr of stocks (in thousands) 38,272 38,292 38,292 39,067 411,072 3,247,913
Reference price 2 3.620 2.950 2.555 1.816 0.0190 0.000900
Announcement Date 4/4/19 4/3/20 4/2/21 3/26/22 3/27/23 4/12/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 5.32 3.946 2.078 1.128 0.595 0.263
EBITDA 1 -36.91 -35.13 -28.3 -27.29 -21.88 -11.94
EBIT 1 -39.24 -36.39 -28.5 -27.37 -21.95 -11.98
Operating Margin -737.61% -922.15% -1,371.27% -2,426.24% -3,688.4% -4,555.89%
Earnings before Tax (EBT) 1 -38.77 -52.09 -28.56 -29.59 -31.69 -18.97
Net income 1 -38.47 -51.83 -28.01 -29.16 -31.68 -18.97
Net margin -723.2% -1,313.41% -1,348.03% -2,584.93% -5,325.21% -7,212.55%
EPS 2 -1.010 -1.353 -0.7315 -0.7591 -0.3727 -0.0115
Free Cash Flow 1 -15.44 -17.86 -16.2 -16.72 -12.32 -6.686
FCF margin -290.26% -452.73% -779.59% -1,482.15% -2,069.81% -2,542.25%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/4/19 4/3/20 4/2/21 3/26/22 3/27/23 4/12/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 2.11 4.43 10.7
Net Cash position 1 85.1 50.7 23.7 - - -
Leverage (Debt/EBITDA) - - - -0.0774 x -0.2022 x -0.8926 x
Free Cash Flow 1 -15.4 -17.9 -16.2 -16.7 -12.3 -6.69
ROE (net income / shareholders' equity) -32.5% -65.7% -72.9% -247% 1,114% 214%
ROA (Net income/ Total Assets) -18.5% -25.3% -35.9% -64.4% -88.9% -80.8%
Assets 1 208.1 205 78.1 45.31 35.65 23.48
Book Value Per Share 2 2.740 1.390 0.6600 -0.0300 -0.0100 -0
Cash Flow per Share 2 1.690 1.110 0.6400 0.2500 0.0100 0
Capex 1 0.2 0.13 0.12 0.03 0.06 0
Capex / Sales 3.67% 3.37% 5.73% 2.84% 9.92% 0.38%
Announcement Date 4/4/19 4/3/20 4/2/21 3/26/22 3/27/23 4/12/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise